AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 15235875
Drug: Iron reduction
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron reduction therapy by biweekly phlebotomy for 3 months
Trial: 28941216
Drug: ABT-122 1
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABT-122 1 mg/kg every other week (4 doses)
Trial: 28941216
Drug: ABT-122 0.5,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABT-122 0.5, 1.5, or 3 mg/kg weekly (8 doses)
Trial: 28941216
Drug: ABT-122 (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABT-122 (all doses)
Trial: 23286311
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg of memantine daily
Trial: 19154996
Drug: Coenzyme Q10
RxNorm normalized name: Coenzyme Q10
DrugBank: Ubidecarenone (DB09270)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Coenzyme Q10 (200 mg daily from 20 weeks of pregnancy until delivery)
Trial: 19154996
Drug: Placebo (daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (daily from 20 weeks of pregnancy until delivery)
Trial: 11704369
Drug: heparin-coated beStent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: heparin-coated beStent
Trial: 7893584
Drug: Isoprenaline (0.25-8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isoprenaline (0.25-8 micrograms) and Metoprolol (0.5-8 mg) administered intravenously
Trial: 3148787
Drug: Insulin alone
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin alone (group A; n = 8)
Trial: 3148787
Drug: 3.5 mg
RxNorm normalized name: niacin 13.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.5 mg b.i.d. glibenclamide plus small amounts of intermediate insulin (group B; n = 8)
Trial: 27546885
Drug: Trebananib plus
RxNorm normalized name: Trebananib
DrugBank: Trebananib (DB12056)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trebananib plus weekly paclitaxel (80mg/m², 3 weeks on/1 week off)
Trial: 27546885
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus weekly paclitaxel (80mg/m², 3 weeks on/1 week off)
Trial: 27546885
Drug: Trebananib plus
RxNorm normalized name: Trebananib
DrugBank: Trebananib (DB12056)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trebananib plus weekly paclitaxel (80mg/m², 3 weeks on/1 week off) in patients with ascites
Trial: 27546885
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus weekly paclitaxel (80mg/m², 3 weeks on/1 week off) in patients with ascites
Trial: 24655690
Drug: Ticagrelor 90
RxNorm normalized name: ticagrelor 90 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ticagrelor 90 mg twice daily with low dose ASA
Trial: 24655690
Drug: Ticagrelor 60
RxNorm normalized name: ticagrelor 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ticagrelor 60 mg twice daily with low dose ASA
Trial: 24655690
Drug: Matching placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo with low dose ASA
Trial: 17101285
Drug: Once daily
RxNorm normalized name: GEL, ONCE DAILY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily 24 microg formoterol in the morning
Trial: 17101285
Drug: Twice daily
RxNorm normalized name: CAPSULE, TWICE DAILY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice daily 12 microg formoterol in the morning and evening
Trial: 14644833
Drug: SprayGel treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SprayGel treatment
Trial: 11034574
Drug: Oral 5‐aminolaevulinic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral 5‐aminolaevulinic acid (ALA) 30 mg/kg
Trial: 8836705
Drug: roxatidine 150
RxNorm normalized name: roxatidine 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: roxatidine 150 mg
Trial: 8495155
Drug: 193 mbar
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 193 mbar treatment in hyperbaric chamber
Trial: 8495155
Drug: 20 mbar
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mbar control treatment
Trial: 24746956
Drug: Cash-based reinforcement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cash-based reinforcement therapy (CBRT)
Trial: 23842010
Drug: Agomelatine (25-50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Agomelatine (25-50 mg/d by mouth)
Trial: 17926007
Drug: RT +/-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RT +/- chemotherapy
Trial: 10847258
Drug: Irbesartan (angiotensin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irbesartan (angiotensin II receptor blocker), once-daily treatment
Trial: 29781089
Drug: Topical piperine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical piperine combined with NB‐UVB
Trial: 29781089
Drug: Topical piperine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical piperine
Trial: 24895382
Drug: Land-based rehabilitation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Land-based rehabilitation treatment
Trial: 20361253
Drug: Pegylated liposomal
RxNorm normalized name: doxorubicin HCl pegylated liposomal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pegylated liposomal doxorubicin (PLD) 40 mg/m(2) every 28 days for six cycles
Trial: 11949773
Drug: Emedastine 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Emedastine 2 mg twice daily
Trial: 11949773
Drug: Emedastine 4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Emedastine 4 mg twice daily
Trial: 11949773
Drug: Alcohol (0.05
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alcohol (0.05 g/dl)
Trial: 10085470
Drug: Capsule A
RxNorm normalized name: capsule administration aid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule A (5 mg MLT)
Trial: 10085470
Drug: Capsule B
RxNorm normalized name: Emend 80mg Capsule BiPack
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule B (10 mg MLT)
Trial: 10085470
Drug: Capsule C
RxNorm normalized name: LIQUID IN CAPSULE CONTAINER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule C (10 mg MLT)
Trial: 30522722
Drug: Pooled monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pooled monotherapy
Trial: 27015912
Drug: Vitamin D3
RxNorm normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D3 supplementation (3000 IU daily for 12 weeks via oral spray solution)
Trial: 25885424
Drug: Diuretic dose
RxNorm normalized name: benazepril and diuretics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diuretic dose adjustment according to the AAD and nonpharmacologic management (fluid and sodium restriction) with four telephone calls over 30 days.
Trial: 25885424
Drug: Standard diuretic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard diuretic dose adjustment by a physician during the first trial visit without telephone follow-up.
Trial: 9735580
Drug: Behavior therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavior therapy with initial weight loss
Trial: 9735580
Drug: Behavior therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavior therapy with weight-loss goals
Trial: 9735580
Drug: Behavior therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavior therapy with achieved weight goals
Trial: 7817735
Drug: Medical abortion
RxNorm normalized name: ABSORPTION BASE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical abortion (mifepristone 600 mg followed 48 h later by gemeprost 1 mg vaginal pessary)
Trial: 3186088
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg ampicillin orally every 6 hours for 10 days
Trial: 3186088
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg erythromycin orally every 6 hours for 10 days
Trial: 51533
Drug: Candicidin therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Candicidin therapy
Trial: 25474502
Drug: Core-Stability (CS)
RxNorm normalized name: MyoGesic-CS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Core-Stability (CS) exercises plus myofascial trigger-point (MTrP) therapy
Trial: 9096993
Drug: Somatulin (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Somatulin (30 mg) administered via intramuscular injections every 10 days for 9 months
Trial: 9096993
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered via intramuscular injections every 10 days for 9 months
Trial: 31412056
Drug: Motor imagery
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Motor imagery practice (MIp): 15 minutes per day, 5 days per week in addition to routine physical therapy
Trial: 31412056
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (CON): routine physical therapy alone
Trial: 27295868
Drug: Abrasivity-matched placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abrasivity-matched placebo formulation (0% CSPS)
Trial: 17511229
Drug: H2-receptor antagonists
RxNorm normalized name: H2-receptor antagonists
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H2-receptor antagonists (H2RAs)
Trial: 17511229
Drug: On-demand treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: On-demand treatment with H2RA
Trial: 12456911
Drug: Intranasal flunisolide
RxNorm normalized name: Flunisolide
DrugBank: Flunisolide acetate (DB14662)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal flunisolide therapy (200 micro g twice a day)
Trial: 10480618
Drug: Acetoacetate (AA)
RxNorm normalized name: ethyl acetoacetate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetoacetate (AA) treatment in normal RBCs (37 degrees C for 24 h)
Trial: 10480618
Drug: BHB treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BHB treatment in normal RBCs
Trial: 10480618
Drug: ACE treatment
RxNorm normalized name: DIMETHICONE 1.5 g in 100 mL TOPICAL CREAM [NIGHTLY FACE TREATMENT - DIMETHICONE]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACE treatment in normal RBCs
Trial: 31800067
Drug: Use of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Use of β‐blockers
Trial: 11895556
Drug: 20 microg
RxNorm normalized name: Calcifediol 20 microgram oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 microg vaccine (Genhevac-B)
Trial: 11895556
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of 20 microg vaccine (Genhevac-B) and 9 MU interferon alpha-2b (Roferon-A)
Trial: 9469336
Drug: r-metHu granulocyte
RxNorm normalized name: pantolactone, (R)-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: r-metHu granulocyte colony-stimulating factor (G-CSF) during continuation therapy
Trial: 9469336
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no G-CSF) during induction phase
Trial: 9469336
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no G-CSF) during continuation therapy
Trial: 17214176
Drug: Human lymphoblastoid
RxNorm normalized name: Insulin Human
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Human lymphoblastoid IFN alpha (Wellferon‐R) at a dosage of 5 MU, thrice weekly for 4 months
Trial: 23024438
Drug: 2.5 mg
RxNorm normalized name: biotin 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg melatonin nightly for 3 weeks
Trial: 19646075
Drug: Pharmacists' interventions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacists' interventions in repeat prescribing, including a pharmacist's interview and annual medication data transfer to prescribing physician.
Trial: 17544597
Drug: Neoadjuvant androgen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant androgen deprivation therapy
Trial: 14712425
Drug: Worsened renal
RxNorm normalized name: Sus scrofa renal pelvis preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Worsened renal function (creatinine level increase > or = 0.3 mg/dL) during HERS
Trial: 11252010
Drug: New combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New combination regimens in phase II cancer clinical trials
Trial: 11252010
Drug: Proposed adjustment
RxNorm normalized name: Propoven
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Proposed adjustment method for standard therapy outcomes
Trial: 8496534
Drug: Thrombolytic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thrombolytic therapy administered to 55 patients 3.2 +/- 2.1 hours after the onset of symptoms.
Trial: 8496534
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (49 patients) without thrombolytic therapy.
Trial: 3573270
Drug: 400 mL
RxNorm normalized name: Lantidra 400 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mL of autologous, previously frozen deglycerolized RBCs
Trial: 3573270
Drug: 100 mL
RxNorm normalized name: PVC IV Bag 100 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mL of saline solution
Trial: 29596102
Drug: Intrathecal clonidine
RxNorm normalized name: Clonidine
DrugBank: Clonidine (DB00575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intrathecal clonidine 75 µg
Trial: 29596102
Drug: Intravenous clonidine
RxNorm normalized name: Clonidine
DrugBank: Clonidine (DB00575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous clonidine 75 µg
Trial: 27912953
Drug: Herbal mouthwash
RxNorm normalized name: Hyperici herba
DrugBank: St. John's Wort (DB01323)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Herbal mouthwash (Matricaria recutita and Mentha piperita), used three times daily for at least 30 seconds, starting one week before HSCT.
Trial: 27912953
Drug: Placebo mouthwash,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo mouthwash, used three times daily for at least 30 seconds, starting one week before HSCT.
Trial: 18301905
Drug: BTX-A injection
RxNorm normalized name: BTX-A
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: BTX-A injection
Trial: 12585101
Drug: Xuesaitong (XST)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xuesaitong (XST) soft capsule
Trial: 9817163
Drug: High molecular
RxNorm normalized name: dextran, high molecular weight
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High molecular weight agents in powder form (two concentrations administered: half and double the one that caused a 20% fall in FEV1)
Trial: 7714943
Drug: ampicillin/sulbactam (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ampicillin/sulbactam (1 g ampicillin/0.5 g sulbactam) plus 1 g probenecid orally
Trial: 7714943
Drug: ceftriaxone (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ceftriaxone (250 mg)
Trial: 2720576
Drug: Controlled-release morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Controlled-release morphine sulfate tablets (MS Contin) given every 12 hours
Trial: 2720576
Drug: Controlled-release morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Controlled-release morphine sulfate tablets (MS Contin) given every 8 hours
Trial: 28355890
Drug: Expressive writing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Expressive writing about thoughts and feelings specific to lymphedema and its treatment
Trial: 28355890
Drug: Writing about
RxNorm normalized name: White Petrolatum
DrugBank: Petrolatum (DB11058)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Writing about daily activities (control)
Trial: 25583588
Drug: Ai Chi
RxNorm normalized name: BUTYLENE GLYCOL 48 g in 240 mL CUTANEOUS TAPE [QIZHOUGUAI Chinese medicine patch]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ai Chi aquatic therapy programme
Trial: 23338547
Drug: Individualized and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individualized and supervised exercise program for pelvic floor muscles (PFM), 8 weeks, twice a week
Trial: 19143690
Drug: Tramadol 3
RxNorm normalized name: TRAMADOL 300MG (RYZOLT) SA TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tramadol 3 mg.kg(‐1)
Trial: 19143690
Drug: Pethidine 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pethidine 0.5 mg.kg(‐1)
Trial: 15481276
Drug: R-salbutamol (0.63
FDA approved: no
EMA approved: no
PMDA approved: no
Description: R-salbutamol (0.63 mg inhaled three times daily for 1 week)
Trial: 15481276
Drug: R,S-salbutamol (1.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: R,S-salbutamol (1.25 mg inhaled three times daily for 1 week)
Trial: 9272411
Drug: Foscarnet administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Foscarnet administered as an infusion twice daily (BID)
Trial: 9272411
Drug: Foscarnet administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Foscarnet administered as an infusion thrice daily (TID)
Trial: 7935029
Drug: Oral conjugated
RxNorm normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral conjugated oestrogens (oCE) + dydrogesterone (DYDR)
Trial: 7935029
Drug: Oral conjugated
RxNorm normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral conjugated oestrogens (oCE) + norethisterone acetate (NETA)
Trial: 7935029
Drug: Transdermal oestradiol
RxNorm normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal oestradiol (tdE2) + dydrogesterone (DYDR)
Trial: 3286509
Drug: Ciprofloxacin (1,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin (1,000 mg daily)
Trial: 3286509
Drug: Norfloxacin (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Norfloxacin (800 mg daily)
Trial: 27362908
Drug: Diluted vasopressin
RxNorm normalized name: Vasopressin
DrugBank: Vasopressin (DB00067)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Diluted vasopressin solution (20 U in 400 ml normal saline)
Trial: 27362908
Drug: Concentrated vasopressin
RxNorm normalized name: Vasopressin
DrugBank: Vasopressin (DB00067)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Concentrated vasopressin solution (20 U in 60 ml normal saline)
Trial: 23775057
Drug: Ziprasidone 320
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ziprasidone 320 mg/d
Trial: 21911976
Drug: H. pylori
RxNorm normalized name: H. PYLORI AGENTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H. pylori treatment group (amoxicillin, clarithromycin, omeprazole for 2 weeks)
Trial: 11573520
Drug: Nicorandil (HD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicorandil (HD group: 0.08 mg kg(‐1) bolus and 0.08 mg kg(‐1) h(‐1) continuous infusion)
Trial: 11573520
Drug: Nicorandil (LD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicorandil (LD group: 0.04 mg kg(‐1) bolus and 0.04 mg kg(‐1) h(‐1) continuous infusion)
Trial: 28819993
Drug: Lactobacillus helveticus-fermented
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactobacillus helveticus-fermented milk drink (190 g/day)
Trial: 28248054
Drug: Testosterone replacement
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone replacement therapy (50 mg of testosterone as a 1% topical gel Androgel for 12 weeks postoperatively)
Trial: 28248054
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no testosterone replacement therapy)
Trial: 28248054
Drug: Testosterone replacement
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone replacement therapy (50 mg of testosterone as a 1% topical gel Androgel)
Trial: 24304332
Drug: Verapamil penile
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verapamil penile injections (12 total injections for six months and subsequently every month for twelve months: total 24 injections) + Iontophoresis with Verapamil/daily + blueberries 160mg/daily + propolis 600mg/daily + Vitamin E 600mg/daily + topical Diclofenac/daily
Trial: 24304332
Drug: Verapamil penile
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verapamil penile injections (and associated treatments)
Trial: 18157071
Drug: Valacyclovir 1
RxNorm normalized name: valacyclovir 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valacyclovir 1 g daily for 60 days
Trial: 16877730
Drug: Letrozole (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Letrozole (2.5 mg daily for 6 months)
Trial: 16877730
Drug: Letrozole plus
RxNorm normalized name: Letrozole
DrugBank: Letrozole (DB01006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Letrozole plus oral cyclophosphamide (50 mg daily for 6 months)
Trial: 16877730
Drug: Letrozole plus
RxNorm normalized name: Letrozole
DrugBank: Letrozole (DB01006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Letrozole plus oral cyclophosphamide
Trial: 1390121
Drug: 8-methoxypsoralen (0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8-methoxypsoralen (0.6 mg/kg)
Trial: 1390121
Drug: 5-methoxypsoralen (1.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-methoxypsoralen (1.2 mg/kg)
Trial: 4005392
Drug: Sustained-release tablets
RxNorm normalized name: Sustained Release Buccal Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained-release tablets containing 40 mg isosorbide dinitrate
Trial: 4005392
Drug: Reference standard-release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference standard-release tablets containing 20 mg isosorbide dinitrate